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A B S T R A C T
Purpose
For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-
based therapy before autologous stem-cell transplantation (ASCT) is as effective as and less toxic
than standard treatment.
Patients and Methods
We randomly assigned 619 patients with relapsed/refractory aggressive lymphoma to treatment
with gemcitabine, dexamethasone, and cisplatin (GDP) or to dexamethasone, cytarabine, and
cisplatin (DHAP). Patients with B-cell lymphoma also received rituximab. Responding patients
proceeded to stem-cell collection and ASCT. Coprimary end points were response rate after two
treatment cycles and transplantation rate. The noninferiority margin for the response rate to GDP
relative to DHAP was set at 10%. Secondary end points included event-free and overall survival,
treatment toxicity, and quality of life.
Results
For the intention-to-treat population, the response rate with GDP was 45.2%; with DHAP the
response rate was 44.0% (95% CI for difference, 9.0% to 6.7%), meeting protocol-defined
criteria for noninferiority of GDP (P .005). Similar results were obtained in a per-protocol analysis.
The transplantation rates were 52.1% with GDP and 49.3% with DHAP (P  .44). At a median
follow-up of 53 months, no differences were detected in event-free survival (HR, 0.99; stratified
log-rank P  .95) or overall survival (HR, 1.03; P  .78) between GDP and DHAP. Treatment with
GDP was associated with less toxicity (P  .001) and need for hospitalization (P  .001), and
preserved quality of life (P  .04).
Conclusion
For patients with relapsed or refractory aggressive lymphoma, in comparison with DHAP,
treatment with GDP is associated with a noninferior response rate, similar transplantation rate,
event-free survival, and overall survival, less toxicity and hospitalization, and superior quality of life.
J Clin Oncol 32:3490-3496. © 2014 by American Society of Clinical Oncology
INTRODUCTION
For patients with aggressive-histology lymphoma
who experience disease progression during or after
primary treatment, the combination of high-dose
chemotherapy and autologous stem-cell transplan-
tation (ASCT) remains the only curative option.
Before proceeding to this therapy, sensitivity to
second-line chemotherapy, as indicated by meeting
treatment response criteria, is a prerequisite.1,2
Second-line treatment with dexamethasone, high-
dose cytarabine, andcisplatin (DHAP) is considered
a standard chemotherapy regimen but is associated
with substantial treatment-related toxicity.1 Aphase
II trial conducted by our group suggested that treat-
mentwith gemcitabine, dexamethasone, and cispla-
tin (GDP) could be administered safely in an
outpatient setting, was well tolerated, efficacious,
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and did not interfere with the ability to collect peripheral blood stem
cells.3,4 We thus hypothesized that treatment with GDP before high-
dose chemotherapy and ASCT would be as effective and associated
with less morbidity compared with DHAP.
PATIENTS AND METHODS
Study Oversight
The NCIC Clinical Trials Group (CTG) LY.12 study was a randomized
controlled trial conducted in 26 Canadian centers, 10 American centers, and
one Australian center, and, in collaboration with the Gruppo Italiano Studio
Linfomi (GISL), 18 centers in Italy. We designed this trial to compare GDP
with DHAP as second-line chemotherapy before ASCT (first random assign-
ment) and to evaluate the efficacy of post-transplantation treatment with the
anti-CD20 antibody rituximab (second random assignment). The results of
the first random assignment are the subject of this report. The LY.12 protocol
was designed by the NCIC CTG Lymphoma Committee. The trial was ap-
proved by the research ethics boards of all participating centers, and written
informed consent was provided by all participants. An independent data and
safety monitoring committee monitored the trial at confidential meetings
every 6 months and evaluated data that were provided at the two interim
analyses.TheNCICCTGoffice inKingston,Ontario,Canada,was responsible
for data management and statistical analysis. The NCIC CTG conducted this
trial with financial support obtained with a grant from the Canadian Cancer
Society Research Institute. Financial support and supply of gemcitabine were
provided by Eli Lilly; rituximab was provided by Roche Canada. The trial was
independently designed, conducted, and analyzed by the NCIC CTG.
Treatment Protocol
Eligible patients were age 18 years or older, with aggressive-histology
lymphoma according to the WHO classification.5 The histologic diagnosis,
including determination of T- or B-cell lineage by immunohistochemistry,
was documented by biopsy before initial therapy or at relapse and confirmed
by a local reference pathologist. Patients with diffuse large B-cell lymphoma
(DLBCL, including variants), peripheral T-cell lymphoma, and anaplastic
large-cell lymphoma were required to have received previous treatment with
one anthracycline-containing chemotherapy regimen. Patients with DLBCL
arising fromabackgroundof follicular or other indolent-histology lymphoma
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Fig 1. CONSORT diagram for NCIC
Clinical Trials Group study LY.12. The
intention-to-treat population (ITT) included
all randomly assigned patients. The per-
protocol (as treated) population (PPP) in-
cluded all eligible patients who received at
least one cycle of assigned protocol therapy.
ASCT, autologous stem-cell transplantation;
DHAP, dexamethasone, cytarabine, and cis-
platin; GDP, gemcitabine, dexamethasone,
and cisplatin.
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were eligible provided that they had received no more than three previous
treatment regimens, with at least one regimen including an anthracycline.
Baseline assessments included physical examination, standard laboratory test-
ing, computed tomography (CT) scanning of the chest, abdomen, and pelvis,
bone marrow biopsy, and, if indicated, CSF analysis (Data Supplement).
Eligible patients were required to have measurable disease by CT scan or
physical examination, an Eastern Cooperative Oncology Group performance
status6 of 0 to 3, and acceptable hematologic and biochemical parameters.
Patientswereexcluded if theyhadpreviously received treatmentwithcisplatin,
cytarabine, or gemcitabine, had CNS involvement with lymphoma, history of
HIV infection, or a medical condition that would interfere with the safe
delivery of the protocol chemotherapy.
Patients were stratified by treating center, International Prognostic In-
dex7 risk factors at trial entry, immunophenotype (B cell v T cell), response to
primary therapy (refractory, relapse at 1 year, or relapse at 1 year) and
previous rituximab treatment, and a concealed random assignment process8
using a computer-generated minimization procedure was performed to allo-
cate patients with equal probabilities to the experimental (GDP) or control
(DHAP) group. Two cycles of protocol therapy were administered at 21-day
intervals andconsistedof either intravenousgemcitabine1,000mg/m2ofbody
surface area per day on days 1 and 8 and cisplatin 75mg/m2 on day 1, and oral
dexamethasone 40mg per day on days 1 through 4 (GDP); or oral dexameth-
asone 40 mg per day on days 1 through 4 and intravenous cytarabine 2 g/m2
over 3 hours once every 12 hours for two doses on day 2 and cisplatin 100
mg/m2 by 24-hour continuous infusion on day 1 (DHAP). Patients who had
not achieved a complete or partial response after two treatment cycles were
permitted to receive a third cycle of protocol therapy. The studywas amended
inNovember2005 toprovidepatientswithCD20 lymphoma treatmentwith
rituximab 375 mg/m2 intravenously on day 1 of each treatment cycle before
the administration of chemotherapy. TreatmentwithGDPwas designed to be
delivered to patients in an outpatient setting and included a recommended
minimumhydration schedule for cisplatin.4 Dose attenuations for treatment-
related toxicity were prescribed (Data Supplement). Patients with a positive
test for hepatitis B surface antigen were recommended to be monitored for
hepatitis B reactivation and to receive lamivudine. Primary prophylaxis against
febrileneutropeniawithgranulocytecolony-stimulatingfactorwasnotmandated.
Eachparticipating centerwas responsible fordeterminingpolicies forhematopoi-
etic stem-cellmobilization, choice of high-dose chemotherapy regimen, support-
ive care after stem-cell reinfusion, and use of post-transplantation involved-field
radiation to areas of bulky disease at relapse or progression.
Assessment of Response and Definition of Study Outcomes
Patients underwent disease re-evaluation after two and, if applicable,
three cycles of protocol therapy. Imaging tests to evaluate remission status
were repeated 3, 7, 13, and 25 months after stem-cell reinfusion and when
clinically indicated. Response assessment was categorized according to the
1999 InternationalWorkingGroup criteria.9 Patients receiving a nonprotocol
salvage chemotherapy regimen that was different from that allocated by ran-
domassignmentwere categorized as having an event andwithdrawn from the
study. The primary end point of response rate by arm after two cycles of
treatment was calculated by considering the number of patients achieving a
complete, unconfirmed complete, or partial response among those randomly
assigned (intention-to-treat analysis) and among those eligible patients who
received at least one cycle of protocol therapy (per-protocol analysis). An
additional, post hoc, per-protocol analysis was performed that also excluded
patients who were alive and without documented disease progression who
were not evaluated after two cycles of treatment. The transplantation rate by
arm was calculated by considering the number of patients categorized as
achieving a response to therapy and meeting criteria for successful stem-cell
mobilization (obtaining at least 2  106 CD34 cells/kg of body weight)
among those receivingat leastonecycleof assignedchemotherapy; a sensitivity
analysis was performed that included all randomly assigned patients. Overall
survival was calculated from the date of random assignment to date of death
from any cause; event-free survival was calculated from the date of random
assignment to the date of objective or symptomatic disease progression, re-
lapse after objective response, initiation of new lymphoma therapy, or death
from any cause. Event-free and overall survivals were evaluated using data
from an intention-to-treat population. Adverse events were graded according
toNational Cancer Institute CommonToxicity Criteria version 2.0.10 Quality
of life (QoL) was measured using the Functional Assessment of Cancer Ther-
apy (FACT) instrument,11 including a subscale for neurologic toxicity and a
lymphoma-specific subscale,12 and was assessed at baseline, end of cycle 1,
middle and end of cycle 2, and 1month after stem-cell infusion. A change in a
QoL item rating of 10% ormore when compared with the baseline value was
considered a clinically meaningful change.
Statistical Analysis
Theprimaryobjective associatedwith thefirst randomassignmentof the
LY.12 trial was to test whether the response rate obtained after two cycles of
GDP was noninferior to the response rate obtained with DHAP. If GDP was
shown to be noninferior, the transplantation rates of GDP and DHAP would
beevaluated for superiorityofGDP.Secondaryobjectives includedcomparing
GDP and DHAP with respect to event-free and overall survival, rates of
successful stem-cell mobilization, frequency of adverse events, QoL, and re-
source usage. Assuming that the response rate obtained would be 50% with
DHAP and 60% with DHAP-rituximab, GDP would be considered noninfe-
rior if the one-sided upper 95%confidence limit for the difference in response
Table 1. Patient Characteristics at Study Entry
Characteristic
GDP
(n  310)
DHAP
(n  309)
No. % No. %
Age, years
Median 55.2 54.6
Range 18.7-71.2 22.6-74.3
 60 88 29.4 89 28.8
Sex
Female 122 39.4 118 38.2
Male 188 60.6 191 61.8
ECOG performance status
0 127 41.0 130 42.1
1 141 45.5 137 44.3
 2 42 13.5 42 13.6
Disease stage
III 79 25.5 76 24.6
IV 138 44.5 134 43.4
Immunophenotype
B 277 89.4 277 89.6
T/null/NK 33 10.6 32 10.4
Histology, lymphoma
Diffuse large B cell 216 71 203 67
Transformed indolent 42 14 45 15
Peripheral T cell 12 4 15 5
Anaplastic large cell 10 3 13 5
Primary mediastinal 6 2 12 4
IPI risk factors at entry
0, 1 115 38 117 38
2 88 29 89 29
 3 100 33 98 32
Response to previous treatment
Complete response  1 year 81 27 83 27
Complete response  1 year 129 42 128 41
No response/progressive disease 95 31 94 30
Previous therapy including
Radiation 76 25 73 24
Rituximab 205 67 205 67
Abbreviations: DHAP, dexamethasone, cytarabine, cisplatin; ECOG, Eastern Coop-
erative Oncology Group; GDP, gemcitabine, dexamethasone, cisplatin; IPI, Interna-
tional Prognostic Index; NK, natural killer.
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ratebetween the twoarmswas less than10%.Toexcludea10%differencewith
80%power, 630 eligible patientswere required. An interim analysis for futility
around the noninferiority end point was planned after 320 patients were
enrolled; the protocol was amended to add a second interim analysis after 480
patients were entered, resulting in a final sample size of 637 patients.
The2 test13 was used to compare the rates of response, transplantation,
adverse events, and successful stem-cell mobilization of the two treatment
arms. The Kaplan andMeier14 life-table method was used to calculate event-
free and overall survivals, and groupswere compared using the log-rank test15
with incorporation of the stratification factors used at random assignment.
Using clinically important change score criteria, responses to each QoL item
were categorized into improved, stable, andworse categories, and a2 test was
performed to compare the distributions of these categories between the two
treatment arms.16All analyseswere performedusing SAS software, version 9.2
(SAS Institute, Cary, NC).
In October 2011, the trial committee recognized that more than 1 addi-
tional year of accrual would be needed to meet the planned sample size. A
request was submitted to the data safety monitoring committee to allow
closure of accrual; this was approved in November 2011.
RESULTS
Patients
From August 2003 to November 2011, we randomly assigned
619 patients. Seven patients were subsequently considered to be inel-
igible, and seven did not receive therapy according to their allocation;
these 14 patients were equally distributed between the two arms (Fig
1). The median age of the patients was 55 years, and 28% were older
than age 60 years. Most patients had stage III or IV and high-
intermediate or high-risk disease7 at random assignment, and had
either not achieved a remission with initial therapy or had recurrence
of lymphoma within 1 year of completing treatment. Seventy-one
percent hadDLBCL, 15%had lymphoma that had transformed from
an indolent B-cell histology; 8% had T-cell or anaplastic large-cell
lymphoma. Among 554 patients with B-cell lymphoma, 411 had re-
ceived rituximab as part of previous therapy (Table 1).
Treatment Outcomes
At least two cycles of protocol therapy were received by 90% of
patients who were allocated to the GDP group (277 of 306 patients)
and 87%of those whowere allocated to theDHAP group (266 of 304
patients). In the intention-to-treat population, the rate of response
after two cycles of treatment was 45.1% in the GDP group and 44.1%
in the DHAP group (P .84). The upper boundary of the one-sided
95.6% CI for the difference in response rates was 5.7%, thus meeting
the protocol-specified criterion for noninferiority of GDP compared
with DHAP (P  .005). The primary and post hoc per-protocol
analyses also met criteria for noninferiority (Table 2). The transplan-
tation rate was 52.1% in the GDP group and 49.3% in the DHAP
group (difference between arms [DHAPGDP], 2.5%; 95% CI,
10.5% to 5.5%; P .44). Similar results were observed among the
intention-to-treat population. The rate of successful stem-cell mobi-
lization (defined as collection of  2.0  106 CD34 cells/kg) was
87.9% in the GDP group and 82.2% in the DHAP group (P .14).
Thirty-three patients treated with GDP and 26 patients receiving
DHAPwhowere planned for transplantation on the basis of response
to protocol therapy did not proceed to ASCT because of disease
progression(GDParm,19patients;DHAParm,13patients)or inabil-
ity to collect stem cells (GDP arm, six patients; DHAP arm, seven
patients; Fig 1).
The median duration of follow-up was 53 months. No differ-
ences were detected in the 4-year event-free survival (HR, 0.99; 95%
CI, 0.82 to 1.21; stratified log-rank P .95; Fig 2A) or overall survival
(HR, 1.03; 95% CI, 0.83 to 1.28; P  .78) of the GDP and DHAP
groups, respectively (Fig 2B).
Table 2. Treatment Outcomes According to Intention-to-Treat, Primary, and Sensitivity Per-Protocol Analyses
Outcome
GDP DHAP
P
Difference (DHAP  GDP)
No. % No. % % 95% CI
Rate of response (CR, CRu,
PR)
Intention-to-treat population† 140 of 310 136 of 309 .005‡ 1.2 9.0 to 6.7
Overall RR 45.1 44.1
CR/CRu 13.5 14.3
PR 31.6 29.8
Primary per-protocol analysis§ 140 of 303 135 of 302 .004‡ 1.5 9.4 to 6.4
Overall RR 46.1 44.7
CR/CRu 13.8 14.6
PR 32.3 30.1
Sensitivity per-protocol
analysis
140 of 287 48.8 135 of 284 47.5 .004‡ 1.3 9.4 to 7.0
Rate of transplantation
Intention-to-treat analysis† 158 of 310 51.0 151 of 309 48.9 .55¶ 2.1 10.0 to 5.8
Per-protocol analysis§ 158 of 303 52.1 149 of 302 49.3 .44¶ 2.5 10.5 to 5.5
Abbreviations: CR, complete response; CRu, complete response unconfirmed; DHAP, dexamethasone, cytarabine, cisplatin; GDP, gemcitabine, dexamethasone,
cisplatin; PR, partial response; RR, response rate.
Includes four patients assessed after one cycle who had durable responses (two PRs, one CRu, one CR).
†Based on 619 patients who were randomly assigned.
‡For noninferiority.
§Based on 605 eligible patients who received at least one dose of assigned therapy.
Based on 571 eligible patients who received at least one dose of assigned therapy and were evaluable for response.
¶For superiority.
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In the multivariable analysis stratified by prognostic variables
used for random assignment, none of the following variables was
predictive of overall response to salvage chemotherapy: treatment
arm, age, performance status, stage III or IV disease, or number of
extranodal sites of disease (Data Supplement). Only advanced-
stage disease was predictive of event-free survival, whereas
advanced stage, poor performance status, and two or more extra-
nodal sites were predictive of overall survival. Response rates ac-
cording to stratification variables were similar and are shown in the
Data Supplement.
Adverse Events, QoL, and Supportive Care
Eightpatients died as a result of protocol treatment–related com-
plications: two during treatment with GDP and six after receiving
DHAP. Grade 3 or 4 adverse events were observed significantly less
frequentlyduring thefirst twocycles of chemotherapyamongpatients
receiving GDP (47% v 61%; P  .001), including fewer episodes of
febrile neutropenia (9% v 23%; P .001; Table 3). QoL assessment,
usingFACT-Total scores, showed that, comparedwithbaseline status,
there was less deterioration among patients who were allocated to
GDP, with significant differences observed at the end of the first cycle
of treatment and at themidpoint of treatment cycle 2 (Fig 3A). At the
midpoint of cycle 2, more patients receiving GDP had an improved
clinicallymeaningful change score (18%v11%)and fewerhadaworse
clinically meaningful change score (33% v 41%; P  .04; Fig 3B)
compared with those treated with DHAP. Patients allocated to GDP
required fewer platelet transfusions (31% v 47%;P .001), including
during the first two cycles of treatment (18% v 32%; P .001). Fewer
patients receiving GDP required hospitalization (47% v 99%; P 
.001), which was consistent with the expectation that this treatment
could be administered to outpatients; in addition, fewer patients ran-
domly assigned to GDP required hospitalization for management of
an adverse event or other illness (18% v 30%; P .001).
DISCUSSION
Patients with aggressive lymphoma and disease progression or recur-
renceafterprimarychemotherapyexperience superioroverall survival
when treated with high-dose chemotherapy and ASCT compared
with continued treatment with standard doses of chemotherapy.1
Several second-line chemotherapy regimens that are designed to in-
crease the proportion of patients eligible for transplantation through
the use of more intense chemotherapy have been evaluated and are
associated with substantial hematologic toxicity and considerable use
of health care resources.17-19 At the time we initiated our study, no
randomized trials comparing salvage chemotherapy regimens had
been conducted. We tested the hypothesis that comparable efficacy
could be achievedwithGDP and that this treatment, administered on
anoutpatient basis,wouldbe associatedwith fewer adverse events and
less frequent hospitalization compared with DHAP.
Our trial is the largest randomized comparison of second-line
chemotherapy regimens administered before autologous stem-cell
transplantation, to our knowledge, and the results confirmed our
hypothesis. We observed that the overall rate of response that was
obtained with GDP was noninferior to DHAP and that GDP was
associated with fewer grade 3 and 4 adverse events, including febrile
neutropenia, less frequent need for hospitalization related to toxicity,
reduced need for platelet transfusion support, and better preservation
of patient-reported QoL. Having met the primary end point of the
trial, we also assessed whether a greater number of patients would
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Fig 2. (A) Progression-free survival for patients randomly assigned to gemcitabine, dexamethasone, and cisplatin (GDP; gold line) or dexamethasone, cytarabine, and
cisplatin (DHAP; blue dashed line). (B) Overall survival for patients randomly assigned to GDP (gold line) or DHAP (blue dashed line). HR, hazard ratio.
Table 3.Most Serious Adverse Events
Adverse Event
GDP
(n  306)
DHAP
(n  304)
PNo. % No. %
Thrombosis/embolism 18 6 18 6 NS
Fatigue 30 10 28 9 NS
Nausea 13 4 25 8 .04
Vomiting 22 7 21 7 NS
Infection
With grade 3 to 4 neutropenia 18 6 28 9 NS
Without neutropenia 21 7 22 7 NS
Febrile neutropenia 28 9 70 23  .001
Syncope 7 2 16 5
Worst overall 143 47 186 61  .001
NOTE. Comparison of most frequently occurring serious adverse events,
occurring in at least 5% of patients who received at least one dose of protocol
therapy, at grade 3 or 4 (National Cancer Institute Common Toxicity Criteria
version 2.0).
Abbreviations: DHAP, dexamethasone, cytarabine, cisplatin; GDP, gemcitabine,
dexamethasone, cisplatin; NS, not significant.
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proceed to transplantation if treated with GDP. Although this end
point was not met, the proportions of patients achieving a stem-cell
collection of  2.0  106 CD34 peripheral blood stem cells/kg
(87.9% v 82.2%) and proceeding to autologous transplantation
(52.1% v 49.3%) seem to be similar with GDP and DHAP,
respectively. Finally, no differences were detected in 4-year event-free
(26% in each group) or overall survivals (39% in each group).
Wechoseresponsetotherapyas theprimaryendpoint for this study
because sensitivity to chemotherapy is a fundamental prerequisite for
proceeding toautologous transplantation.Theresponse rateweobserved
seems to be less than that reported byGisselbrecht et al,2 who compared
rituximab plus DHAPwith rituximab, ifosfamide, carboplatin, and eto-
poside. Eligibility for that trial was restricted to patients with DLBCL,
whereas our study included patients with transformed indolent lym-
phoma andT-cell lymphoma. In addition,more than 70%of patients in
our study either did not achieve a remission with primary therapy or
experienced recurrence within 1 year of completing that therapy,
factors that predict for a lower rate of response and poorer
event-free survival.19 Nonetheless, the proportion of patients
proceeding to transplantation in both studies was similar, as
was overall survival after 3 years of follow-up.20 The proportion
of patients event-free 4 years after transplantation was 53% in
the study by Gisselbrecht et al,21 which is similar to that ob-
served in the current study (43% for GDP and 49% for DHAP;
Data Supplement).
Outcomes after ASCT for patients with aggressive lymphoma
have consistently been shown to be related to clinical variables that
include International Prognostic Index risk factors22 and previous
exposure to theCD20antibodyrituximab,20,23 inaddition tohistology
and previous response duration. Recently, it has been recognized that
germinal center B-cell and activated B-cell subtypes of DLBCL, de-
finedbygene expressionprofiling, havedistinctmolecular origins and
natural histories, which may also account for variability in outcomes
after ASCT.24 An exploratory analysis by Thieblemont et al25 of im-
munohistochemical andmolecular profiling of biopsies frompatients
who experienced relapse suggests that response to different salvage
regimens may not be uniform between these subtypes of aggressive
lymphoma, providing a potential avenue, if confirmed, for selective
addition of agents that target these genetic differences. We are cur-
rently analyzingbiopsy samples frompatientswhowere enrolledonto
our trial to determine if cell of origin and othermolecular biomarkers
are correlated with response and long-term outcomes.
In summary, for patients with relapsed or refractory aggressive-
histology lymphoma, treatment with GDP before high-dose chemo-
therapy andASCT is as effective asDHAPand is associatedwith fewer
adverse events, less frequent need for hospitalization, and superior
patient-reportedQoL.This treatment canbe considered the preferred
treatment option for these patients.
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